Patent · US Active

Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof

US10167298B2 · kind B2 · utility

0Cited by

27References

17Claims

0Family size

Assignee

Merck Sharp & Dohme LLC · US

Inventors

Michael McNevin · Berkeley Heights, US
Yong Liu · Shanghai, CN
Ian Mangion · Cranford, US
Alfred Lee · Lawrence, US
Joyce Stellabott · Perkasie, US
Benjamin D. Sherry · New York, US
Gary Martin · Green Brook, US
Kung-I Feng · Berkeley Heights, US
Scott Schultz · Maplewood, US
Ryan Cohen · Piscataway, US
Yanfeng Zhang · Suzhou, CN

Key dates

Filing date	Oct 24, 2014
Grant date	Jan 1, 2019
Priority date	—
Expiry date	Oct 24, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P1/16
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.